LDLR and familial hyperaldosteronism: Because of statins’ mechanism of action, homozygous FH individuals with null mutations on the LDLR gene are expected to be unresponsive to statin treatment, as these medications lower the LDL-C concentration to some extent by enhancing LDLR expression in the liver [17].